+249.5%
MRVL vs GSK
+31.2%
+218.3%
-48.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.0% | -1.9% | +9.0% | +6.7% |
| 7D | +3.2% | -1.8% | +5.0% | +2.9% |
| 30D | +5.9% | -2.2% | +8.1% | +5.6% |
| 3M | -29.3% | -1.8% | -27.5% | -29.5% |
| 6M | +186.5% | -10.6% | +197.1% | +187.0% |
| YTD | +163.4% | +4.4% | +159.0% | +168.5% |
| 1Y | +249.5% | +30.4% | +219.1% | +282.3% |
| All | +249.5% | +31.2% | +218.3% | +282.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling